Updated on 18 February 2016
The combined revenue for the two companies for the year-ended 2015 is over USD 230 million.
This acquisition is the second landmark acquisition in Cipla's 80 year history - the first was Cipla Medpro, South Africa.
The acquisition will give scale to Cipla's US business - currently 8% of total revenue as well as providing a launch pad to introduce Cipla's pipeline of products in respiratory and injectables, among others, in the coming years.
Combined with the pipeline of InvaGen products, the overall portfolio will be wide-ranging and will cover chronic therapies like CVS, CNS, respiratory, oncology and diabetes among others.